Investing.com - Mylan (NASDAQ:MYL) reported on Thursday fourth quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Mylan announced earnings per share of $1.4 on revenue of $3.19B. Analysts polled by Investing.com anticipated EPS of $1.28 on revenue of $3.22B. That with comparison to EPS of $1.3 on revenue of $3.08B in the same period a year before. Mylan had reported EPS of $1.17 on revenue of $2.96B in the previous quarter. Analysts are expecting EPS of $0.93 and revenue of $2.64B in the upcoming quarter.
Mylan shares are down 7.36% from the beginning of the year , still down 36.45% from its 52 week high of $29.30 set on March 21, 2019. They are under-performing the Nasdaq which is down 5.23% year to date.
Mylan follows other major Healthcare sector earnings this month
Mylan's report follows an earnings beat by Merck&Co on February 5, who reported EPS of $1.16 on revenue of $11.87B, compared to forecasts EPS of $1.15 on revenue of $11.98B.
Novartis ADR had beat expectations on January 29 with fourth quarter EPS of $1.32 on revenue of $12.4B, compared to forecast for EPS of $1.31 on revenue of $12.33B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar